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ABSTRACT
Background    Fucoidan is derived from seaweed wide-
ly used in Japanese cuisine, but little is known about its 
influence on glucose metabolism. To obtain information 
about the physiological effects of fucoidan on glucose 
metabolism, the digestive system, and the gustatory 
system controlling taste sensation in patients with type 
2 diabetes, we conducted a randomized, double-blind, 
placebo-controlled study.
Methods    Thirty patients with type 2 diabetes on diet 
therapy were recruited from an outpatient clinic (22 
men and 8 women aged 59.10 ± 13.24 years, body mass 
index: 25.18 ± 3.88, hemoglobin A1c: 7.04 ± 1.24%). 
They were divided into 2 groups and underwent 2 in-
terventions with a 4-week interval. One group received 
fucoidan for 12 weeks (a daily 60 mL test beverage con-
taining 1,620 mg of fucoidan) and then placebo (60 mL) 
for the subsequent 12-week period, while the order was 
reversed in the other group. Evaluation was performed 
just before and after each intervention. Taste sensitivity 
was measured for 5 basic tastes by the filter paper disk 
method and food intake was evaluated with a validated 
diet questionnaire.
Results    No adverse events occurred during the study 
period. Despite no change of the diet, stool frequency 
increased during fucoidan intake (from 7.78 ± 4.64/week 
in Week 1 to 9.15 ± 5.03/week in Week 5, P < 0.001), and 
it increased more in lean subjects. In 11 subjects whose 
stool frequency exceeded the mean value, the thresh-
olds for sweet, salty, bitter and umami tastes were 
significantly reduced (enhancement of sensitivity) after 
fucoidan intake. In 14 subjects with normal HOMA-IR 
(homeostatic model assessment of insulin resistance, 
< 2.5), hemoglobin A1c decreased after fucoidan intake 
(from 6.73 ± 1.00 to 6.59 ± 1.00%, P < 0.05), as did the 
fasting plasma level of GLP-1 (glucagon-like peptide-1, 
from 6.42 ± 3.52 to 4.93 ± 1.88 pmol/L, P < 0.05).
Conclusion    Sustained fucoidan intake led to alter-
ations of gastrointestinal function, including increased 
stool frequency and enhanced taste sensitivity, which 
could contribute to better control of diabetes.
Key words    dietary fiber; fucoidan; glucagon-like 
peptide1; taste sensitivity; type 2 diabetes mellitus
In dietary therapy for diabetes, appropriate energy in-
take, nutritional balance and timing of meals are consid-
ered to be important factors.1–3 With regard to nutritional 
balance, it is important for the diet to contain a certain 
amount of fiber in addition to appropriate amounts of 
carbohydrates and lipids.4 To achieve sufficient intake of 
dietary fiber, it has been reported that premodern firm 
foods with high dietary fiber content are more suitable 
than modern Westernized soft foods with low dietary 
fiber content.5
 Regarding dietary fiber, it has been reported that 
soluble dietary fiber, which seaweed contains in large 
amounts, slows the absorption of carbohydrate and 
improves the intestinal environment including bacterial 
flora.6–10 In particular, microbiota-accessible carbohy-
drate (MAC) in dietary fiber is involved in growth of the 
intestinal flora and regulation of the intestinal environ-
ment.11 Furthermore, it has been reported that expression 
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of the intestinal sweet taste receptor is altered in type 
2 diabetes,12 which is one of the possible links between 
deterioration of the intestinal environment affecting taste 
receptors to alter their sensitivity and impairment of car-
bohydrate/lipid metabolism such as insulin resistance, 
obesity and diabetes.13, 14
 In the present study, we focused on high molecular 
weight fucoidan extracted from “mozuku,” a seaweed 
commonly used in healthy Japanese dishes.15, 16 Animal 
studies have shown that fucoidan with low molecular 
form influences glucose metabolism, including the 
promotion of insulin secretion, pancreatic protection, 
improvement of insulin resistance and inhibiting the 
progression of diabetic nephropathy.17–23 However, 
only a few animal studies using high molecular weight 
fucoidan were performed so far because of its rather 
labile nature despite an ample history of use as foods in 
humans. In fact, high molecular weight fucoidan was 
reported to increase intestinal peristalsis in humans,24 
whereas its effects on diabetes and glucose metabolism 
have not been investigated so far.
 Accordingly, to clarify the effects of high molecular 
weight fucoidan on diabetes when administered for a 
long period, we planned a randomized, double-blind, 
placebo-controlled study in patients who had not re-
ceived pharmacotherapy for diabetes. We investigated 
the effects of long-term intake of high molecular weight 
fucoidan on various biochemical parameters of diabetic 
control. In order to assess the influence of the intestinal 
environment on taste sensation, we also analyzed the 




Out of the patients with type 2 diabetes attending the 
outpatient clinic of Hakuai Hospital, Japan from March 
through April 2015 who were on diet therapy only, 30 
patients who gave consent were enrolled in the study. 
They included 22 men and 8 women aged 59.10 ± 13.24 
years (mean ± SD, range: 30–79 years), with a body 
mass index (BMI) of 25.18 ± 3.88 kg/m2, hemoglobin 
A1c (HbA1c) of 7.04 ± 1.24% and fasting plasma glu-
cose (FPG) of 7.59 ± 2.21 mmol/L.
 Out of the 30 subjects, two subjects discontinued 
the study before completion (one subject failed to ingest 
(4) 
(3) Intake of fucoidan 
n = 14 
Informed consent (consent to participate) 
n = 30 
Patients with type 2 diabetes attending an outpatient clinic 
n = 30 
Randomization n = 30 
Intake of placebo 
n = 15 
Intake of fucoidan 
n = 15 
Washout period 
n = 15 
Intake of placebo 
n = 15 
Washout period 
n = 15 Discontinuation　n = 1 
(Transferred to another 
hospital) 










n = 14 
Evaluation 
n = 14 
(2) 
(1) 
Fig. 1. Study design. This was a randomized, double-blind, placebo-controlled, cross-over study. Evaluations were conducted at times (1) 
to (4). Evaluations included the diet history, number of bowel movements, stool characteristics, clinical parameters, biochemistry tests and 
assessment of the taste threshold (sweetness, saltiness, sourness, bitterness and umami).
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the study drink as instructed, and the other subject was 
transferred to another hospital), and 28 subjects were 
included in the analysis (Fig. 1). Data for discontinued 
subjects were excluded from analysis.
Study design and intervention
This was a randomized, double-blind, placebo-controlled, 
cross-over study (Clinical trial registration number: 
UMIN 000031171).
 The subjects received numbers in the order of giving 
informed consent, and subjects with odd numbers were 
assigned to Group A while those with even numbers 
were assigned to Group B. Group A ingested fucoidan 
for the first intervention, followed by placebo for the 
second intervention, while the order was reversed in 
Group B. The first intervention involved daily intake of 
fucoidan or placebo for 12 weeks and was followed by a 
4-week washout period, after which the study treatments 
were switched for the second 12-week intervention peri-
od (Fig. 1).
Study treatments (fucoidan and placebo)
Fucoidan
The fucoidan beverage (Fucomin, Marine Products 
Kimuraya , Sakaiminato, Japan) used as the study drug 
contained 810 mg (dry weight) of high molecular weight 
fucoidan (molecular weight: 240,000, sulfate content: 
13%) per 30 mL.15, 16 One dose of this beverage (30 mL) 
was taken before breakfast and dinner (60 mL/day). The 
safety of fucoidan was previously confirmed up to 4,050 
mg/day in an overdose study conducted by Abe et al.25 
Placebo
The placebo beverage (30 mL twice daily= 60 mL/
day) contained purified water and starch for viscosity. 
Its color was adjusted with synthetic colorant until the 
appearance was identical to the active beverage. Because 
fucoidan does not have any taste or smell, taste was not 
adjusted.
Parameters evaluated
Evaluation of the following parameters was conducted 
before and after the first and second interventions (Fig. 1).
Food intake
Food intake was evaluated by using the brief-type 
self-administered diet history questionnaire. This ques-
tionnaire assesses food intake over a 1-month period, 
and the mean time required to answer it is approximate-
ly 15 minutes.26, 27 Based on the responses submitted, a 
nutritional value program was used to calculate the daily 
intake of 30 different nutrients and 50 different foods for 
each subject.
Bowel movements and stool characteristics
During the intervention period, the presence/absence of 
abdominal signs, number of bowel movements, and stool 
characteristics were documented by the subjects using 
record sheets. The number of bowel movements was 
evaluated on a weekly basis. Stool characteristics were 
recorded by referring to illustrations showing scales for 
hardness and color (darkness).28 Hardness was classified 
into 6 grades ranging from 1 (soft) to 6 (hard), while 
color was classified into 7 grades ranging from light 
brown (1) to dark brown (7). The stool record sheets 
were collected every 4 weeks.
Clinical data and biochemical parameters
Clinical data were collected from the medical records, 
including the height, weight, BMI, body fat, abdominal 
circumference and blood pressure. A fasting morning 
blood sample was collected to measure baseline levels 
of HbA1c, fasting plasma glucose (FPG), triglycerides, 
total cholesterol, high density lipoprotein-cholesterol 
(HDL-C), low density lipoprotein-cholesterol (LDL-C), 
aspartate transaminase (AST), alanine aminotransferase 
(ALT), γ-glutamyl transpeptidase (g-GTP), baseline 
glucagon-like peptide-1 (GLP-1), high molecular weight 
(HMW) adiponectin, insulin, leptin and zinc.
 The plasma GLP-1 level was measured by a 
solid-phase enzyme immunoassay kit (GLP-1 Active 
Form Assay Kit-IBL, Immuno-Biological Laboratories, 
Fujioka, Japan) using a blood sample collected in a tube 
containing an anticoagulant and protease inhibitors 
(BD™ P800 Blood Collection System, NJ). Serum 
HMW adiponectin and leptin levels were measured 
with enzyme-linked immunosorbent assay kits (High 
Molecular Weight Adiponectin ELISA Kit, Otsuka 
Pharmaceutical, Tokyo, Japan; and Human Leptin 
Quantikine ELISA Kit, R&D Systems, MN, respective-
ly).
 The homeostatic model assessment of insulin re-
sistance (HOMA-IR) was used as the index to measure 
insulin resistance. HOMA-IR was calculated as fasting 
insulin (mU/mL) × fasting plasma glucose (mmol/L)/22.5.
Taste threshold
Thresholds for recognition of the 5 basic tastes (sweet-
ness, saltiness, sourness, bitterness and umami) were 
evaluated by the filter paper disk method. A filter paper 
disk (5 mm in diameter) soaked with a taste solution was 
applied to the tip of the tongue, which is innervated by 
the chorda tympani nerve, for 3 seconds with the mouth 
open. Taste solutions of 5 different concentrations were 
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applied in order from low to high, and the taste recogni-
tion threshold was defined as the concentration that the 
subject identified correctly. The threshold was classified 
as Concentration 1 to Concentration 5 in the order of low 
to high concentrations, and the result was recorded as 
Concentration 6 if a subject could not identify the taste 
at Concentration 5.
 Assessment was conducted in the order of sweet-
ness, saltiness, sourness, umami and bitterness. To elim-
inate residual taste, the subjects gargled with water and a 
one-minute interval was set between each taste test.
 Taste Discs (Sanwa Kagaku Kenkyusho, Nagoya, 
Japan) were used to test sweetness, saltiness, sourness 
and bitterness.29–31 For umami, Ajinomoto (Ajinomoto, 
Tokyo, Japan) conta in ing 97.5% monosodium 
L-glutamate and 2.5% 5-ribonucleotide sodium was 
used (Table 1).
Table 1. Reagents and solutions for the taste test
Concentration levels
Taste type Reagent 1 2 3 4 5
Sweetness Purified white sugar (g/dL) 0.3 2.5 10 20 80
Saltiness Sodium chloride (g/dL) 0.3 1.25 5 10 20
Sourness Tartaric acid (g/dL) 0.02 0.2 2 4 8
Bitterness Quinine hydrochloride (g/dL) 0.01 0.02 0.1 0.5 4
Umami Monosodium glutamate (g/dL) 0.03 0.1 0.25 0.5 1
 Subjects were asked to fast from 21:00 on the day 
before testing. Smoking was prohibited from 30 minutes 
prior to testing. In order to reduce the influence of envi-
ronmental factors, the test was done in a quiet room at a 
temperature of 25ºC.
Statistical Analysis
SPSS ver. 21.0 was used for statistical analysis. Results 
are expressed as the mean ± SD. The paired t-test was 
used for comparison between before and after interven-
tion, while the unpaired t-test was used for intergroup 
comparisons. Multivariate analysis (multiple regression 
analysis) was conducted using HbA1c as a dependent 
variate. In all analyses, the level of significance was 5%.
Ethical considerations
Patients received written and oral explanations about the 
purpose and methods of this study, and written informed 
consent was obtained from all subjects prior to enrol-
ment. 
 This study was approved by the Institutional 
Review Board of Tottori University Faculty of Medicine 
(February 2015, Approval ID: 2642) and was performed 
according to the Declaration of Helsinki.
RESULTS
Food intake
Daily food intakes including seaweeds did not show any 
significant difference between fucoidan and placebo 
groups (seaweeds: 12.37 ± 10.88 vs 9.87 ± 11.96 g/day). 
Intake of fucoidan or placebo did not lead to any signifi-
cant changes of food intake in the subjects. 
Bowel movements and stool characteristics
The number of bowel movements increased significantly 
with fucoidan intake (7.78 ± 4.64 /week in Week 1, 9.15 
± 5.03 /week in Week 5, P < 0.001). The change in the 
number of bowel movements (difference between Weeks 
1 and 5) was also significantly larger with fucoidan 
intake (+1.37 ± 1.86 /week with fucoidan intake versus 
+0.20 ± 1.61 /week with placebo intake, P < 0.05, Table 
2). Stool hardness and color were not significantly differ-
ent between fucoidan and placebo intake.
Clinical data and biochemical parameters
Analysis of the overall study population
After intake of fucoidan or placebo, there were no 
significant changes of the BMI, blood pressure, fasting 
plasma glucose, HbA1c, serum lipids, hepatic function 
and zinc. After fucoidan intake, a significant decrease 
of the baseline GLP-1 and HDL-C levels was observed. 
The leptin level was significantly increased after placebo 
intervention (Table 3).
 Taste thresholds of the 28 subjects before the inter-
vention were compared with those of 108 healthy adults 
reported in a literature,32 which showed significant 
elevation in the subjects with diabetes for sweetness (3.36 
± 1.50 vs 2.44 ± 1.12, P < 0.01) and sourness (3.18 ± 1.31 
vs 2.59 ± 1.07, P < 0.05).
Analysis of subjects whose bowel movements increased 
during fucoidan intake
Since there were marked individual variations in the 
response of bowel movements to fucoidan, clinical 
data were compared before and after fucoidan intake 
in 11 subjects (7 men and 4 women) in whom the mean 
increase of bowel movements was above average. No 
significant changes of the parameters occurred after 
placebo intervention, but fucoidan intervention resulted 
in a significant increase of leptin and a significant de-
crease of the baseline GLP-1 level (leptin: before: 0.36 ± 
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Table 2. Changes of bowel movements and stool characteristics during the intervention period
Intervention n Week 1 Week 5 Week 5 - Week 1
No. of bowel movements (times/w) Fucoidan intake 27 7.78 ± 4.64** 9.15 ± 5.03** +1.37 ± 1.86*
Placebo intake 26 6.89 ± 2.69 7.23 ± 3.00 +0.20 ± 1.61*
Stool hardness (grades 1–6) Fucoidan intake 27 3.15 ± 0.94 3.24 ± 0.72 +0.24 ± 0.81
Placebo intake 25 3.30 ± 0.86 3.20 ± 0.99 +0.08 ± 0.78
Stool color (grades 1–7) Fucoidan intake 26 3.13 ± 1.28 3.15 ± 1.02 -0.19 ± 1.18
Placebo intake 26 3.20 ± 0.97 3.07 ± 1.05 -0.30 ± 0.63
*: P < 0.05, **: P < 0.005
The number of bowel movements per week is shown, and stool hardness and color are the mean results for 1 week.
Table 3. Parameters before and after each intervention (overall study population)
Parameter
n Fucoidan intake n Placebo intake
Before After Before After
Clinical Body weight (kg) 28 69.00 ± 13.42 68.71 ± 13.28 26 70.30 ± 13.32 69.96 ± 13.36
BMI (kg/m2) 23 25.01 ± 4.03 24.89 ± 4.07 22 25.94 ± 3.77 25.77 ± 3.69
Body fat (%) 22 28.15 ± 6.24 28.17 ± 6.40 22 29.79 ± 6.58 29.90 ± 6.28
Waist circumference (cm) 22 88.92 ± 11.22 89.20 ± 13.40 22 89.67 ± 10.54 89.76 ± 11.56
Systolic blood pressure (mmHg) 19 135.00 ± 14.82 135.74 ± 17.85 19 136.63 ± 18.25 134.53 ± 15.06
Diastolic blood pressure (mmHg) 19 77.68 ± 14.96 76.74 ± 11.74 19 79.74 ± 10.86 77.63 ± 11.62
Biochemical FPG (mmol/L) 28 7.60 ± 2.33 7.22 ± 1.67 26 7.05 ± 1.61 7.33 ± 1.78
HbA1c (%) 28 6.99 ± 1.31 6.93 ± 1.21 27 6.85 ± 1.06 6.89 ± 1.12
Insulin (pmol/mL) 28 57.60 ± 46.20 58.20 ± 39.00 26 63.60 ± 64.80 53.40 ± 28.20
HOMA-IR 28 3.08 ± 2.36 3.07 ± 2.02 26 3.33 ± 3.36 2.90 ± 1.61
Leptin (nmol/L) 28 0.45 ± 0.38 0.50 ± 0.38 26 0.46 ± 0.34* 0.52 ± 0.35*
HMW-adiponectin (μmol/L) 28 0.21 ± 0.18 0.21 ± 0.20 26 0.19 ± 0.21 0.19 ± 0.19
GLP-1 (pmol/L) 28 6.29 ± 3.47* 5.18 ± 2.70* 26 5.95 ± 1.98 5.71 ± 2.31
LDL-C (mmol/L) 25 3.18 ± 0.85 3.15 ± 0.70 24 3.13 ± 0.70 3.18 ± 0.72
HDL-C (mmol/L) 24 1.56 ± 0.54* 1.48 ± 0.44* 23 1.49 ± 0.49 1.53 ± 0.49
Triglyceride (mmol/L) 24 1.51 ± 0.88 1.57 ± 0.99 23 1.75 ± 1.30 1.68 ± 1.05
T-cholesterol (mmol/L) 15 5.61 ± 1.19 5.46 ± 0.80 13 5.46 ± 0.67 5.48 ± 0.75
AST (U/L) 18 23.17 ± 12.56 28.06 ± 22.52 15 30.07 ± 21.98 29.53 ± 20.62
ALT (U/L) 19 29.68 ± 25.30 32.26 ± 30.48 15 37.73 ± 33.34 36.93 ± 27.46
γ-GTP (U/L) 19 49.84 ± 44.46 52.21 ± 59.88 15 54.60 ± 55.60 57.27 ± 65.73
Zinc (mmol/L) 28 12.48 ± 1.29 12.03 ± 1.35 26 12.76 ± 1.62 12.58 ± 1.45
Data are the mean ± SD; *: P < 0.05.
AST, aspartate transaminase; ALT, alanine aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; γ-GTP, γ-glutamyl transpep-
tidase; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein-cholesterol; HMW, high molecular weight; 
HOMA-IR, homeostatic model assessment of insulin resistance; LDL-C, low density lipoprotein-cholesterol; T-cholesterol, total cholesterol.
0.30 nmol/L, after: 0.51 ± 0.43 nmol/L, baseline GLP-
1: before: 5.70 ± 1.76 pmol/L, after: 4.76 ± 2.22 pmol/L, 
Table 4). 
 Regarding the taste threshold, significant decreases 
of the following thresholds were observed only after 
fucoidan intervention: sweetness (before: 3.30 ± 1.34, 
after: 2.10 ± 0.88), saltiness (before: 2.60 ± 0.97, after: 
1.70 ± 0.67), bitterness (before: 3.20 ± 1.23, after: 2.10 ± 
0.88) and umami (before: 5.20 ± 0.92, after: 4.20 ± 1.40, 
Fig. 2).
Analysis of the subgroup with HOMA-IR < 2.5 before in-
tervention
In the group with an above average increase of bowel 
movements, HOMA-IR values were lower before inter-
vention compared to those of the group with a below 
average increase of bowel movements (group with above 
average increase of bowel movement: 2.62 ± 1.39 times/
week, group with below average increase of bowel 
movement: 2.99 ± 2.14 times/week). Accordingly, clin-
ical parameters were compared in 14 subjects (10 men 
and 4 women) in whom HOMA-IR was not above the 
normal range (< 2.5).
19
Fucoidan trial in diabetes with taste testing
Table 4. Parameters before and after intervention (subgroup with an increase of bowel movements after fucoidan)
Parameter
n Fucoidan intake n Placebo intake
Before After Before After
Clinical Body weight (kg) 11 65.44 ± 7.48 64.76 ± 8.04 11 65.64 ± 7.52 65.28 ± 7.89
BMI (kg/m2) 11 24.95 ± 2.71 24.69 ± 2.81 11 25.03 ± 2.76 25.02 ± 2.79
Body fat (%) 9 28.24 ± 6.23 27.90 ± 6.43 11 28.78 ± 7.97 29.41 ± 7.36
Waist circumference (cm) 10 86.12 ± 5.97 87.28 ± 6.64 11 87.16 ± 5.76 86.00 ± 7.49
Systolic blood pressure (mmHg) 9 135.22 ± 17.06 135.22 ± 16.97 5 147.00 ± 22.55 141.40 ± 19.27
Diastolic blood pressure (mmHg) 9 80.33 ± 16.78 75.67 ± 14.35 5 77.80 ± 8.90 72.60 ± 13.45
Biochemical FPG (mmol/L) 11 8.10 ± 2.05 7.83 ± 1.83 11 7.55 ± 2.00 7.99 ± 2.16
HbA1c (%) 11 7.58 ± 1.08 7.38 ± 1.00 11 7.36 ± 1.07 7.35 ± 1.20
Insulin (pmol/L) 11 43.20 ± 39.00 46.20 ± 26.40 11 45.00 ± 39.00 43.80 ± 25.20
HOMA-IR 11 2.49 ± 1.90 2.62 ± 1.39 11 2.55 ± 2.16 2.61 ± 1.58
Leptin (nmol/L) 11 0.36 ± 0.30* 0.51 ± 0.43* 11 0.40 ± 0.33 0.47 ± 0.39
HMW-adiponectin (μmol/L) 11 0.23 ± 0.21 0.19 ± 0.19 11 0.21 ± 0.21 0.22 ± 0.23
GLP-1 (pmol/L) 11 5.70 ± 1.76* 4.76 ± 2.22* 11 5.33 ± 1.75 5.12 ± 2.59
LDL-C (mmol/L) 9 3.15 ± 0.85 3.10 ± 0.65 10 2.95 ± 0.80 3.13 ± 0.80
HDL-C (mmol/L) 9 1.59 ± 0.75 1.57 ± 0.62 10 1.51 ± 0.59 1.57 ± 0.62
Triglycerides (mmol/L) 9 1.76 ± 1.41 1.63 ± 1.41 10 1.80 ± 1.80 1.67 ± 1.35
T-cholesterol (mmol/L) 6 5.51 ± 1.19 5.38 ± 0.80 4 4.73 ± 0.49 5.04 ± 0.75
AST (U/L) 3 22.67 ± 12.50 27.33 ± 15.37 5 22.60 ± 9.13 23.60 ± 4.72
ALT (U/L) 3 32.33 ± 18.77 36.33 ± 22.23 5 26.20 ± 16.00 26.80 ± 7.52
γ-GTP (U/L) 3 42.00 ± 18.33 38.67 ± 20.43 5 34.40 ± 18.88 33.60 ± 14.28
Zinc (mmol/L) 11 12.45 ± 0.87 12.01 ± 1.42 11 12.96 ± 1.47 12.59 ± 1.70
Data are the mean ± SD; *: P < 0.05. 
AST, aspartate transaminase; ALT, alanine aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; γ-GTP, γ-glutamyl transpep-
tidase; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein-cholesterol; HMW, high molecular weight; 



































































































P < 0.05 P < 0.05 
P < 0.05 P < 0.05 n.s.
After
n.s.
Placebo Fucoidan Placebo Fucoidan Placebo
Fucoidan Placebo Fucoidan Placebo
Fig. 2. Comparison of the taste threshold before and after intervention (subgroup with an increase of bowel movements after fucoidan). 
Conc., Concentration; n.s., not signifi cant.
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 A significant decrease of HbA1c and the baseline 
GLP-1 level was observed only after fucoidan intake 
(HbA1c: before: 6.73 ± 1.00%, after: 6.59 ± 1.00%, base-
line GLP-1: before: 6.42 ± 3.52 pmol/L, after: 4.93 ± 1.88 
pmol/L). The leptin level increased significantly after 
intake of both fucoidan and placebo (Table 5).
Multiple regression analysis
Multiple regression analysis was conducted using HbA1c 
after fucoidan intervention as a dependent variable and 
other parameters (leptin, HMW-adiponectin, baseline 
GLP-1 and HOMA-IR) after fucoidan intervention as 
independent variables. As a result, no parameter was 
significantly associated with an increase or decrease of 
HbA1c.
Adverse events
No adverse events were observed during the intervention 
period, including symptoms, objective signs and abnor-
mal biochemistry data.
DISCUSSION
A relationship between diabetes and the gustatory 
system has attracted lots of attention since the discovery 
of taste receptors on the intestinal epithelium where 
augmentation of insulin secretion is provoked through 
the incretin pathway.33–37 Accordingly, this randomized, 
double-blind, placebo-controlled, cross-over study inves-
tigated the effects of long-term intake of high molecular 
weight fucoidan on clinical parameters, the intestinal 
environment, and the gustatory system controlling taste 
sensation in patients with type 2 diabetes. 
 Studies conducted so far have indicated that high 
intake of fucoidan is safe, and does not induce abnor-
malities of the gastrointestinal tract or stool condition.25 
However, it has been reported that intestinal absorption 
of minerals, specifically zinc, is inhibited when a large 
amount of dietary fiber is taken for a long period.38, 39 
Therefore, it was a concern that long-term intake of fu-
coidan, a form of dietary fiber, might reduce the serum 
zinc level,17  which may in turn lead to the impairment 
of taste sensation.40 As a results, there was no significant 
decrease of the serum zinc level with both fucoidan and 
placebo intake in this intervention study. 
 On the other hand, HDL-C and the baseline GLP-1 
level both decreased significantly after intake of fu-
coidan. The decrease of GLP-1 is discussed below with 
the subgroup analysis. While the mechanism of these 
Table 5. Clinical parameters before and after intervention (subgroup with HOMA-IR < 2.5)
Parameter
n Fucoidan intake n Placebo intake
Before After Before After
Clinical Body weight (kg) 14 61.11 ± 7.94 60.31 ± 8.27 13 62.39 ± 8.62 62.31 ± 8.99
BMI (kg/m2) 11 22.92 ± 2.53 22.44 ± 2.17 13 23.35 ± 2.53 23.32 ± 2.54
Body fat (%) 10 25.24 ± 5.86 24.75 ± 5.63 10 27.11 ± 5.88 27.30 ± 5.85
Waist circumference (cm) 10 81.02 ± 7.67 81.08 ± 8.58 11 84.20 ± 8.95 83.59 ± 10.87
Systolic blood pressure (mmHg) 12 131.00 ± 12.49 130.92 ± 14.64 11 134.00 ± 15.31 130.36 ± 12.40
Diastolic blood pressure (mmHg) 12 75.67 ± 10.79 75.33 ± 10.59 11 78.18 ± 9.89 73.64 ± 6.96
Biochemical FPG (mmol/L) 14 7.05 ± 1.72 6.77 ± 1.72 13 7.16 ± 1.72 7.11 ± 1.94
HbA1c (%) 14 6.73 ± 1.00* 6.59 ± 1.00* 14 6.74 ± 1.00 6.61 ± 1.00
Insulin (pmol/L) 14 28.80 ± 10.20 36.60 ± 16.20 13 28.80 ± 9.60 34.20 ± 18.60
HOMA-IR 14 1.47 ± 0.48 1.79 ± 0.77 13 1.52 ± 0.50 1.55 ± 1.14
Leptin (nmol/L) 14 0.22 ± 0.16* 0.31 ± 0.29* 13 0.23 ± 0.16* 0.31 ± 0.22*
HMW-adiponectin (μmol/L) 14 0.28 ± 0.27 0.27 ± 0.26 13 0.23 ± 0.26 0.21 ± 0.23
GLP-1 (pmol/L) 14 6.42 ± 3.52* 4.93 ± 1.88* 13 6.01 ± 3.48 5.08 ± 2.41
LDL-C (mmol/L) 13 3.15 ± 0.98 3.15 ± 0.75 12 3.03 ± 0.85 3.18 ± 0.72
HDL-C (mmol/L) 13 1.86 ± 0.65 1.76 ± 0.49 11 1.81 ± 0.67 1.78 ± 0.59
Triglycerides (mmol/L) 13 1.23 ± 0.87 0.99 ± 0.37 12 1.16 ± 0.87 1.11 ± 0.67
T-cholesterol (mmol/L) 12 5.69 ± 1.19 5.38 ± 0.8 7 5.28 ± 0.91 5.25 ± 0.8
AST (U/L) 3 16.00 ± 1.73 19.33 ± 2.08 4 21.00 ± 10.10 25.50 ± 5.69
ALT (U/L) 4 20.25 ± 1.50 20.75 ± 3.30 4 22.00 ± 2.94 25.75 ± 5.85
γ-GTP (U/L) 4 36.75 ± 10.69 34.75 ± 15.69 4 48.50 ± 22.75 58.00 ± 31.44
Zinc (mmol/L) 14 12.50 ± 1.06 11.80 ± 1.04 13 12.47 ± 1.27 12.10 ± 1.38
Data are the mean ± SD; *: P < 0.05.
AST, aspartate transaminase; ALT, alanine aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; γ-GTP, γ-glutamyl transpep-
tidase; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein-cholesterol; HMW, high molecular weight; 
HOMA-IR, homeostatic model assessment of insulin resistance; LDL-C, low density lipoprotein-cholesterol; T-cholesterol, total cholesterol.
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changes is unclear, the results suggested that both pa-
rameters should be monitored when fucoidan is used for 
a long period. However, none of the changes of clinical 
and biochemical parameters were classified as adverse 
events. Accordingly, it was considered that long-term 
intake of fucoidan is feasible in diabetic patients on diet 
therapy.
 This study also demonstrated a significant increase 
in the number of bowel movements after fucoidan 
intake. A previous report suggested that fucoidan intake 
increases intestinal peristalsis in middle-aged subjects.24 
Fucoidan is a water-soluble dietary fiber that provides 
microbiota-accessible carbohydrate (MAC) to some 
intestinal bacteria. After that, MAC is digested in the 
intestine which generates organic acids there. These 
organic acids reduce the intestinal pH and enhance peri-
stalsis, and the acidic intestinal environment also inhib-
its growth of undesirable bacteria such as Clostridium 
welchii and increases the number of beneficial bacteria 
such as Bifidobacteria.41–43 These changes of the intes-
tinal environment during long-term intake of fucoidan 
may have led to the increase of bowel movements. 
Although none of the subjects complained about the 
increase of bowel movements, this should be explained 
before patients start long-term intake of fucoidan.
 The subgroup with an above average increase in the 
number of bowel movements showed a decrease of the 
baseline GLP-1 level, an increase of leptin and increased 
sensitivity to 4 tastes (except sourness) after intake of 
fucoidan. Recently, it was demonstrated that taste recep-
tors are expressed throughout the entire gastrointestinal 
tract epithelium,33–37 and that sweetness receptors in the 
small and large intestines are involved in the secretion 
of GLP-1.44–47 In this context, it is possible that the 
changes of GLP-1 and the taste threshold could be due 
to modulation of the intestinal environment by fucoidan 
intake. In short, fucoidan may have altered the intestinal 
environment as a prebiotics, thus affecting the regulation 
of GLP-1 secretion via intestinal taste receptors.
 Furthermore, the group with an above average in-
crease of bowel movements had lower HOMA-IR values 
compared to the group with a below average increase. 
Accordingly, a subgroup without insulin resistance 
(HOMA-IR < 2.5) was extracted and clinical parameters 
were compared. Interestingly, a significant decrease of 
HbA1c and the baseline GLP-1 level was seen after in-
take of fucoidan in this subgroup. This finding suggests 
that intestinal changes related to fucoidan intake may 
lead to improvement of glucose metabolism when insu-
lin sensitivity remains normal.48–51 
 Decreased taste sensitivity was documented in 
patients with diabetes observed in this study or reported 
in literatures,52 which presumably comes from the cause 
other than diabetic neuropathy. It is believed to have a 
close link with a possible deterioration in the nutrient 
sensing and incretin secretion systems both held on the 
intestinal epithelium to augment insulin secretion.37 In 
this regard, the enhancement of taste sensitivity and the 
subtle, but significant decrease in HbA1c following the 
fucoidan intervention, which have not been documented 
before as a result of an RCT trial, seem to provide a rea-
sonable assumption that restoration of the intestinal and 
oral environment by some prebiotics such as fucoidan 
could ameliorate diabetes control through the nutrient 
sensing and the incretin secretion systems. Determining 
postprandial GLP-1 levels could have contributed to it.
 There are reports showing suppressive effect of 
leptin on taste responses,53 which could spoil the fu-
coidan effect. The results of leptin levels in this study, 
however, were equivocal. They rose after fucoidan and/
or after placebo depending on the subgroup studied. The 
elevation of leptin by fucoidan may have been related 
to incidental weight gain by a small number of subjects 
during the study, because the leptin level reflects body 
fat mass and it also increased after placebo intake.
 There have been interesting reports about im-
provement of the intestinal microflora by a low fat and 
high fiber diet, suggesting that foods rich in dietary 
fiber such as fucoidan may be beneficial.54–56 And also, 
employment of high molecular weight fucoidan in the 
present study in humans still has a novelty in regard to 
its advantage as possible candidates for functional food 
with health-promoting benefits. That is because it has 
an ample history of use as foods in humans despite its 
poorer animal studies than those using low molecular 
weight fucoidan.
 This study had several limitations. First, the number 
of bowel movements and stool characteristics (color 
and form) were used as indices for assessment of the 
intestinal environment, but evaluation of other relevant 
parameters such as characteristics in intestinal microflo-
ra, fatty acid levels, variations in fucoidan dosage, etc., 
might have influenced the conclusions. Second, only 28 
subjects were analyzed in this study. If more subjects 
had been enrolled for analysis, significant changes of 
other parameters might have been observed. Third, all 
of the subjects were Japanese. Since bacterial strains 
that can utilize seaweed constituents as MAC may be 
present in the intestinal flora of Japanese individuals 
due to their high dietary intake of seaweed,57 we must 
be careful when attempting to apply the conclusions of 
this study to other ethnic populations. Fourth, there re-
mains the possibility that some food rich in dietary fiber 
could replace the effect obtained by fucoidan ingestion, 
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whereas fucoidan still has substantial advantages for its 
ample history of use as dietary fiber in humans as well 
as for the documented evidence of probability based 
on the results of the RCT trial in this article. Fifth, the 
biochemical and gustatory findings in humans observed 
in the study are not supported by their corresponding 
findings in animal models because of the lack of study 
using high molecular weight fucoidan in animals.
Acknowledgments: The authors would like to express their sincere 
appreciation to all those who contributed to the study, especially 
to Dr. Yosuke Horikoshi, Tottori University, Japan for his advice 
about data analysis. We would like to thank the staff at Hakuai 
Hospital, who kindly cooperated with collecting clinical data for 
this study.
    Part of this study was conducted with financial support from 
JSPS Grant-in-Aid 16K12023 and Kimuraya Research Aid 2015.
Conflicts of interest
Chieko Sakai, Minoru Kouzuki, Hisashi Shimohiro, Yoshie Ota, 
Hironori Sakinada, Tatsuo Takeuchi, Tsuyoshi Okura and Keiichi 
Hanaki declare that they have no conflicts of interest. Sunao 
Abe is an employee of Marine Products Kimuraya Co., Ltd. and 
Takeshi Kasagi is a consultant for Marine Products Kimuraya Co., 
Ltd.
REFERENCES
  1 American Diabetes A, Bantle JP, Wylie-Rosett J, Albright 
AL, Apovian CM, Clark NG, et al. Nutrition recommenda-
tions and interventions for diabetes: a position statement of 
the American Diabetes Association. Diabetes Care. 2008;31 
Suppl 1:S61-78. PMID: 18165339.
  2 Anderson JW, Randles KM, Kendall CW, Jenkins DJ. 
Carbohydrate and fiber recommendations for individuals with 
diabetes: a quantitative assessment and meta-analysis of the 
evidence. J Am Coll Nutr. 2004;23:5-17. PMID: 14963049.
  3 Koyama T, Yoshita K, Okuda N, Saitoh S, Sakata K, 
Okayama A, et al. Overall nutrient and total fat intake among 
Japanese people: The INTERLIPID Study Japan. Asia Pac J 
Clin Nutr. 2017;26:837-48. PMID: 28802293.
  4 Fujii H, Iwase M, Ohkuma T, Ogata-Kaizu S, Ide H, Kikuchi 
Y, et al. Impact of dietary fiber intake on glycemic control, 
cardiovascular risk factors and chronic kidney disease in 
Japanese patients with type 2 diabetes mellitus: the Fukuoka 
Diabetes Registry. Nutr J. 2013;12:159. PMID: 24330576.
  5 Sonnenburg ED, Sonnenburg JL. Starving our microbial self: 
the deleterious consequences of a diet deficient in microbiota-
 accessible carbohydrates. Cell Metab. 2014;20:779-86. PMID: 
25156449.
  6 Anderson JW, Midgley WR, Wedman B. Fiber and diabetes. 
Diabetes Care. 1979;2:369-77. PMID: 510132.
  7 Jenkins DJ, Wolever TM, Leeds AR, Gassull MA, Haisman P, 
Dilawari J, et al. Dietary fibres, fibre analogues, and glucose 
tolerance: importance of viscosity. Br Med J. 1978;1:1392-4. 
PMID: 647304.
  8 Post RE, Mainous AG, 3rd, King DE, Simpson KN. Dietary fiber 
for the treatment of type 2 diabetes mellitus: a meta-analysis. J 
Am Board Fam Med. 2012;25:16-23. PMID: 22218620.
  9 Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman 
D, Jenkins DJ, et al. Dietary fiber, glycemic load, and risk 
of NIDDM in men. Diabetes Care. 1997;20:545-50. PMID: 
9096978.
10 Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, 
Hoffmann K, Boeing H. Fiber and magnesium intake and inci-
dence of type 2 diabetes: a prospective study and meta-analysis. 
Arch Intern Med. 2007;167:956-65. doi: 10.1001/archinte.167.9.956.
11 Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, 
Wingreen NS, Sonnenburg JL. Diet-induced extinctions 
in the gut microbiota compound over generations. Nature. 
2016;529:212-5. PMID: 26762459.
12 Young R, Chia B, Isaacs NJ, Ma J, Khoo J, Wu T, et al. 
Disordered control of intestinal sweet taste receptor expres-
sion and glucose absorption in type 2 diabetes. Diabetes. 
2013;62:3532-41. PMID:23761104
13 Karlsson F, Tremaroli V, Nielsen J, Backhed F. Assessing 
the human gut microbiota in metabolic diseases. Diabetes. 
2013;62:3341-9. PMID: 24065795.
14 Wang J, Jia H. Metagenome-wide association studies: 
fine-mining the microbiome. Nat Rev Microbiol. 2016;14:508-
22. PMID: 27396567.
15 Ohshiro T, Harada N, Kobayashi Y, Miki Y, Kawamoto H. 
Microbial fucoidan degradation by Luteolibacter algae H18 
with deacetylation. Biosci Biotechnol Biochem. 2012;76:620-
3. doi: 10.1271/bbb.110911.
16 Yoshimoto M, Higaki K, Nanba E, Ikeguchi M. Anti-
Proliferation Activity of Fucoidan in MKN45 Gastric Cancer 
Cells and Downregulation of Phosphorylated ASK1, a Cell 
Cycle-Regulated Kinase. Yonago Acta Med. 2015;58:1-7. 
PMID: 26190891.
17 Fitton JH, Stringer DN, Karpiniec SS. Therapies from 
Fucoidan: An Update. Mar Drugs. 2015;13:5920-46. PMID: 
26389927.
18 Jiang X, Yu J, Ma Z, Zhang H, Xie F. Effects of fucoidan 
on insulin stimulation and pancreatic protection via the 
cAMP signaling pathway in vivo and in vitro. Mol Med Rep. 
2015;12:4501-7. PMID: 26130492.
19 Kim KJ, Yoon KY, Lee BY. Fucoidan regulate blood glucose 
homeostasis in C57BL/KSJ m+/+db and C57BL/KSJ db/db 
mice. Fitoterapia. 2012;83:1105-9. PMID: 22580164.
20 Shan X, Liu X, Hao J, Cai C, Fan F, Dun Y, et al. In vitro and 
in vivo hypoglycemic effects of brown algal fucoidans. Int J 
Biol Macromol. 2016;82:249-55. PMID: 26601762.
21 Song MY, Ku SK, Kim HJ, Han JS. Low molecular weight 
fucoidan ameliorating the chronic cisplatin-induced de-
layed gastrointestinal motility in rats. Food Chem Toxicol. 
2012;50:4468-78. PMID: 23022014.
22 Wang Y, Nie M, Lu Y, Wang R, Li J, Yang B, et al. Fucoidan 
exerts protective effects against diabetic nephropathy related 
to spontaneous diabetes through the NF-kappaB signaling 
pathway in vivo and in vitro. Int J Mol Med. 2015;35:1067-73. 
PMID: 25672488.
23 Wang Y, Wang J, Zhao Y, Hu S, Shi D, Xue C. Fucoidan from 
sea cucumber Cucumaria frondosa exhibits anti-hyperglycemic 
effects in insulin resistant mice via activating the PI3K/PKB 
pathway and GLUT4. J Biosci Bioeng. 2016;121:36-42. PMID: 
26194305.
24 Miyoshi M, Abe S, Kasagi T, Hiramatsu K, Ikeda T. Effects 
of Mozuku-Derived High-Molecular-Weight Fucoidan on 
lntestinal Motility. J Yonago Med Ass. 2013;64:69-77.
25 Abe S, Hiramatsu K, Ichikawa O, Kawamoto H, Kasagi T, 
Miki Y, et al. Safety evaluation of excessive ingestion of mo-
zuku fucoidan in human. J Food Sci. 2013;78:T648-51. PMID: 
23465035.
23
Fucoidan trial in diabetes with taste testing
26 Kobayashi S, Honda S, Murakami K, Sasaki S, Okubo H, 
Hirota N, et al. Both comprehensive and brief self-administered 
diet history questionnaires satisfactorily rank nutrient intakes 
in Japanese adults. J Epidemiol. 2012;22:151-9. PMID: 
22343326.
27 Kobayashi S, Murakami K, Sasaki S, Okubo H, Hirota 
N, Notsu A, et al. Comparison of relative validity of food 
group intakes estimated by comprehensive and brief-type 
 self-administered diet history questionnaires against 16 
d dietary records in Japanese adults. Public Health Nutr. 
2011;14:1200-11. PMID: 21477414.
28 Lewis SJ, Heaton KW. Stool form scale as a useful guide to 
intestinal transit time. Scand J Gastroenterol. 1997;32:920-4. 
PMID: 9299672.
29 Negoro A, Umemoto M, Fujii M, Kakibuchi M, Terada T, 
Hashimoto N, et al. Taste function in Sjogren’s syndrome 
patients with special reference to clinical tests. Auris Nasus 
Larynx. 2004;31:141-7. PMID: 15121223.
30 Tomita H, Horikawa Y. Dissociated taste disorder. Auris 
Nasus Larynx. 1986;13 Suppl 1:S17-23. PMID: 3767771.
31 Yamashita H, Nakagawa K, Nakamura N, Abe K, Asakage T, 
Ohmoto M, et al. Relation between acute and late irradiation 
impairment of four basic tastes and irradiated tongue volume 
in patients with head-and-neck cancer. Int J Radiat Oncol Biol 
Phys. 2006;66:1422-9. PMID: 17084561.
32  Instruction manual for TasteDisk. Sanwa Kagaku Kenkyusho 
Nagoya, Japan.
33 Dyer J, Salmon KS, Zibrik L, Shirazi-Beechey SP. Expression 
of sweet taste receptors of the T1R family in the intestinal tract 
and enteroendocrine cells. Biochem Soc Trans. 2005;33:302-
5. PMID: 15667333.
34 Janssen S, Depoortere I. Nutrient sensing in the gut: new 
roads to therapeutics? Trends Endocrinol Metab. 2013;24:92-
100. PMID: 23266105.
35 Kokrashvili Z, Mosinger B, Margolskee RF. Taste signaling 
elements expressed in gut enteroendocrine cells regulate 
 nutrient-responsive secretion of gut hormones. Am J Clin 
Nutr. 2009;90:822S-5S. PMID: 19571229.
36 Oda M, Seta Y, Kataoka S, Toyono T, Toyoshima K, 
Morimoto Y. Expression patterns of T1R3 in duodenal epi-
thelial cells with some gastrointestinal hormone. Arch Histol 
Cytol. 2010;73:177-85. doi: 10.1679/aohc.73.177.
37 Trivedi BP. Neuroscience: hardwired for taste. Nature. 
2012;486:S7-9. PMID: 22717403.
38 Shah M, Chandalia M, Adams-Huet B, Brinkley LJ, Sakhaee 
K, Grundy SM, et al. Effect of a high-fiber diet compared with 
a moderate-fiber diet on calcium and other mineral balances 
in subjects with type 2 diabetes. Diabetes Care. 2009;32:990-
5. PMID: 19279300.
39 Wisker E, Nagel R, Tanudjaja TK, Feldheim W. Calcium, 
magnesium, zinc, and iron balances in young women: effects 
of a low-phytate barley-fiber concentrate. Am J Clin Nutr. 
1991;54:553-9. PMID: 1652199.
40 Matsugasumi M, Hashimoto Y, Okada H, Tanaka M, 
Kimura T, Kitagawa N, et al. The Association Between Taste 
Impairment and Serum Zinc Concentration in Adult Patients 
With Type 2 Diabetes. Can J Diabetes. 2018; 42:520-524. 
PMID: 29551654
41 Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, 
Gordon JI, et al. Energy-balance studies reveal associations 
between gut microbes, caloric load, and nutrient absorption in 
humans. Am J Clin Nutr. 2011;94:58-65. PMID: 21543530.
42 Shang Q, Shan X, Cai C, Hao J, Li G, Yu G. Dietary fucoidan 
modulates the gut microbiota in mice by increasing the abun-
dance of Lactobacillus and Ruminococcaceae. Food Funct. 
2016;7:3224-32. PMID: 27334000.
43 Yu SH, Wu SJ, Wu JY, Wen DY, Mi FL. Preparation of 
fucoidan-shelled and genipin-crosslinked chitosan beads for 
antibacterial application. Carbohydr Polym. 2015;126:97-107. 
PMID: 25933528.
44 Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim 
BJ, Zhou J, et al. Gut-expressed gustducin and taste receptors 
regulate secretion of glucagon-like peptide-1. Proc Natl Acad 
Sci U S A. 2007;104:15069-74. PMID: 17724330.
45 Rasoamanana R, Darcel N, Fromentin G, Tome D. Nutrient 
sensing and signalling by the gut. Proc Nutr Soc. 2012;71:446-
55. PMID: 22453062.
46 Steinert RE, Gerspach AC, Gutmann H, Asarian L, Drewe J, 
Beglinger C. The functional involvement of gut-expressed sweet 
taste receptors in glucose-stimulated secretion of glucagon-like 
peptide-1 (GLP-1) and peptide YY (PYY). Clin Nutr. 
2011;30:524-32. PMID: 21324568.
47 Takai S, Yasumatsu K, Inoue M, Iwata S, Yoshida R, 
Shigemura N, et al. Glucagon-like peptide-1 is specifically 
involved in sweet taste transmission. FASEB J. 2015;29:2268-
80. PMID: 25678625.
48 Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica 
D, et al. Metabolic endotoxemia initiates obesity and insulin 
resistance. Diabetes. 2007;56:1761-72. PMID: 17456850.
49 Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda 
T, et al. The gut microbiota suppresses insulin-mediated fat 
accumulation via the short-chain fatty acid receptor GPR43. 
Nat Commun. 2013;4:1829. PMID: 23652017.
50 Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, 
Keilbaugh SA, et al. Linking long-term dietary patterns with 
gut microbial enterotypes. Science. 2011;334:105-8. PMID: 
21885731.
51 Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone 
RL, et al. Acetate mediates a microbiome-brain-beta-cell 
axis to promote metabolic syndrome. Nature. 2016;534:213-7. 
PMID: 27279214.
52 De Carli L, Gambino R, Lubrano C, Rosato R, Bongiovanni D, 
Lanfranco F, et al. Impaired taste sensation in type2 diabetic 
patients without chronic complications:a case-control study. J 
Endocrinol Invest. 2018;41:765-772. PMID: 29185232.
53 Rodrigues L, Espanca R, Costa AR, Antunes CM, Pomar 
C, Capela-Silva F, Pinheiro CC, et al. Association between 
Salivary Leptin Levels and Taste Perception in Children. J 
Nutr Metab. 2017;2017:7260169. PMID: 28811937.
54 Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, 
Comelli EM. Adiposity, gut microbiota and faecal short 
chain fatty acids are linked in adult humans. Nutr Diabetes. 
2014;4:e121. PMID: 24979150.
55 Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, 
Kimura I. Dietary gut microbial metabolites, short-chain fatty 
acids, and host metabolic regulation. Nutrients. 2015;7:2839-
49. PMID: 25875123.
56 Licht TR, Hansen M, Poulsen M, Dragsted LO. Dietary 
carbohydrate source influences molecular fingerprints of the 
rat faecal microbiota. BMC Microbiol. 2006;6:98. PMID: 
17137493.
57 Hehemann JH, Correc G, Barbeyron T, Helbert W, Czjzek 
M, Michel G. Transfer of carbohydrate-active enzymes 
from marine bacteria to Japanese gut microbiota. Nature. 
2010;464:908-12. PMID: 20376150.
